SAM #b6d47be754344b59b6518daa61c750d1

Solicitation for New Vaccine Platforms (NVP) Program by HHS ASPR/BARDA

This opportunity from HHS ASPR/BARDA seeks proposals for the New Vaccine Platforms (NVP) Program to advance innovative vaccine platform technologies. - Objective: Identify and develop new vaccine platforms for BARDA's medical countermeasure portfolio - Targeted technologies: - Protein-based platforms - Viral vector-based platforms - Bacterial vector-based platforms - Requirements: - Platforms must have demonstrated manufacturing of Phase 1 clinical trial material - Offerors may be single organizations or teams combining antigen expression and vaccine carrier/formulation capabilities - Staged capability demonstration: - Must address at least two emerging infectious disease threats - Initial options: Lassa virus, Nipah virus, chikungunya virus, West Nile virus - Additional options: pandemic influenza and other CBRN-aligned threats - No specific OEMs or vendors are named - Place of performance: Washington, DC - No product line items specified; primary focus is on service-based demonstrations

Description

The New Vaccine Platforms (NVP) Program aims to identify new vaccine platforms for the BARDA medical countermeasure (MCM) portfolio and advance them through a staged capability demonstration to identify technologies that (1) are safe; (2) are effective across multiple infectious disease threats from different pathogen families; and (3) enable efficient development and manufacturing.

In-scope platform technologies notionally include protein, viral vector, and bacterial vector-based approaches that have demonstrated manufacturing of Phase 1 clinical trial material (CTM). The Request for Project Proposals is expected to be open to Offerors that are either (1) a single organization with a full technology solution or (2) a two-part team that together offer a full technology solution comprised of an antigen expression capability (Capability A) and a vaccine carrier/formulation capability (Capability B).

The objective of the NVP Program is to conduct a staged capability demonstration (CD) across at least two (2) emerging infectious disease (EID) threats. CD stages include: (CD-1) manufacturing demonstration (all work from start to Phase 1 CTM); (CD-2) nonclinical demonstration (all critical path activities to support a Phase 1 IND; e.g., safety, immunogenicity, efficacy); and (CD-3) clinical demonstration (Phase 1 trial). Threat options are informed by the BARDA mission and the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) priority biological threats, which includes select Emerging Infectious Diseases (EID) families or groups. Options for initial demonstration across two (2) EID threats notionally include: Lassa virus; Nipah virus; chikungunya virus; or West Nile virus. Additional options for further demonstration may include a to-be-determined (TBD) pandemic influenza target and a TBD infectious disease threat aligned to the BARDA CBRN Division mission.

Advancing vaccine platforms that are safe, broadly protective across multiple infectious disease threats, and enable streamlined development and manufacturing will help ensure the U.S. MCM portfolio is optimally positioned to respond efficiently and effectively to national health security incidents. Additional Links:Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) priority biological threatsRapid Response Partnership Vehicle

View original listing